Electronic Supplementary Material (ESI) for Biomaterials Science.

In vitro vascularization of tissue engineered constructs by non-viral delivery of pro-angiogenic genes

Helena R. Moreira[a,b,c], Rosanne M. Raftery[d,e,f], Lucília P. da Silva[a,b], Mariana T. Cerqueira[a,b], Rui L. Reis[a,b,c], Alexandra P. Marques[a,b,c], Fergal J. O'Brien*[d,e,f]

Supporting Information



Figure S1. Metabolic activity and DNA quantification in transfected hDFbs immediately after the procedure. Results are expressed as the mean ± standard deviation where n=3, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.



Figure S2. Assessment of the viability of delivering only non-viral vectors on hDFbs (i) and only plasmids (ii) on cell viability. The amount of non-viral vector or plasmid added was the amount that did not react and was calculated from the SybrSafe exclusion assay. Control corresponds to hDFbs non transfected. Results are expressed as the mean ± standard deviation (n=3), * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$ in relation to every condition at day 3.